Otitis media vaccine - Intercell

Drug Profile

Otitis media vaccine - Intercell

Alternative Names: Vaccine against middle ear infections - Intercell

Latest Information Update: 09 Mar 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intercell
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Otitis media; Otorhinolaryngological infections

Most Recent Events

  • 24 Feb 2010 Discontinued - Preclinical for Otitis media in European Union (unspecified route)
  • 24 Feb 2010 Discontinued - Preclinical for Otorhinolaryngological infections in European Union (unspecified route)
  • 19 Nov 2006 Preclinical trials in Otitis media in European Union (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top